Skip to main content

IL-6

cancer search news magnify
For autoimmune patients with a history of malignancy, the initiation of biologic or targeted synthetic disease modifying agents (bDMARD/tsDMARDs) may provoke concern. While data for biologic…
RT @Janetbirdope: #Bestinclass. #Giantcellarteritis GCA lots of novel ideas. V short prednisone- 2 months with #Tocilizu

Janet Pope Janetbirdope

1 month ago
#Bestinclass. #Giantcellarteritis GCA lots of novel ideas. V short prednisone- 2 months with #Tocilizumab. Not RCT. Looked safe & effective but too small to know if blindness etc are increased. Don’t suggest you try this at home...yet! @RheumNow @eular_org #EULAR2022 OP0185
RT @RichardPAConway: Unizony et al. GCA outcome on/after tocilizumab. 36.5% relapse after stopping tocilizumab. Generall

Richard Conway RichardPAConway

1 month ago
Unizony et al. GCA outcome on/after tocilizumab. 36.5% relapse after stopping tocilizumab. Generally stopped due to remission, 10% stopped due to adverse event @RheumNow #EULAR2022 POS0267 https://t.co/jlZDTinfCK
RT @RichardPAConway: Schmitt et al. Pharmacokinetic study of IV tocilizumab in 24 patients with known GCA. Using 6mg/kg

Richard Conway RichardPAConway

1 month ago
Schmitt et al. Pharmacokinetic study of IV tocilizumab in 24 patients with known GCA. Using 6mg/kg or 7mg/kg. Effective on lab measures and no GCA flares. @RheumNow #EULAR2022 POS0268 https://t.co/uhxfGZvYTw
RT @RichardPAConway: Tomelleri @tomelleri_a et al. GCA. Tocilizumab weekly x 1 year, then every other week x 1 year, the

Richard Conway RichardPAConway

1 month ago
Tomelleri @tomelleri_a et al. GCA. Tocilizumab weekly x 1 year, then every other week x 1 year, then stop. 2 PMR flares during toc. 1 month post-stop 100% remission. 6 months post-stop 24% GCA flare! Some patients seem to need indefinite toc @RheumNow #EULAR2022 POS0266 https://t.co/8I5GQ08HDr
Puzzle pieces
Infiltrating macrophages expressing IL-6 and GM-CSF may drive the subacromial bursitis often seen in polymyalgia rheumatica, according to new research (abstract OP0015) presented on the first day of…
RT @RichardPAConway: Sanchez-Martin et al. Tocilizumab in newly diagnosed vs refractory GCA. 471 patients. Appears of re

Richard Conway RichardPAConway

1 month ago
Sanchez-Martin et al. Tocilizumab in newly diagnosed vs refractory GCA. 471 patients. Appears of relatively similar efficacy in both groups. Surprising that the difference is not greater given refractory GCA inherently more complex @RheumNow #EULAR2022 POS0817 https://t.co/HEWzYCz9YD
RT @RichardPAConway: Preito-Pena at al. Tocilizumab in LVV-GCA and TAK. Similar responses in both, with 75% showing comp

Richard Conway RichardPAConway

1 month ago
Preito-Pena at al. Tocilizumab in LVV-GCA and TAK. Similar responses in both, with 75% showing complete clinical response but only 20% complete imaging response at month 12. Clinical implications of these persistent imaging findings need clarification @RheumNow #EULAR2022 POS0804 https://t.co/sNbRzIkwnt
RT @RichardPAConway: Unizony et al. Case series of tocilizumab + 8 weeks steroid in GCA. 30 patients, 50% new 50% relaps

Richard Conway RichardPAConway

1 month ago
Unizony et al. Case series of tocilizumab + 8 weeks steroid in GCA. 30 patients, 50% new 50% relapsing. 77% in sustained remission at week 52! No vision loss. Exciting, needs an RCT @RheumNow #EULAR2022 OP0185 https://t.co/ohBYIWYxBC https://t.co/fsn4x17Hwv
×